gip glp 1 agonist Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes GLP1 agonists: current and future

Saha, N., Hong, S

Acknowledgments This work is part of the collaboration between the Department of Radiobiology and Molecular Genetics, VINA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia, Clinic for Internal Medicine, Department of Endocrinology and Diabetes, Zemun Clinical Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia, and KAUST

Regulators are concerned that making the medicine widely available could lead to: Misdiagnosis: Patients self-treating a different, underlying condition

Minimal response may warrant increasing by 50-100mcg